Precision Optics Corp. POCI
- Market cap
- $52.3M
- P/E
- 0.0×
Follow POCI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 | 1.20 | 1.23 | 3.15 | 1.65 | 4.35 | 1.95 | 5.45 | 3.47 | 3.77 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 2.10 | 1.95 | 5.55 | 6.12 | 6.75 | 9.00 | 7.85 | 7.20 | 6.90 | 5.34 |
High Price
|
|||
| 33 | 27 | 30 | 62 | 60 | 52 | 77 | 85 | 84 | 90 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 4 | 3 | 4 | 7 | 10 | 11 | 16 | 21 | 19 | 19 |
Revenue
|
|||
| 24.05% | 24.53% | 36.70% | 31.19% | 33.89% | 32.17% | 31.43% | 36.75% | 30.35% | 17.83% |
Gross Margin
|
|||
| (1) | (1) | 0 | (1) | (1) | 0 | (1) | 0 | (3) | (6) |
EBT
|
|||
| (26.40%) | (31.88%) | (8.68%) | (9.02%) | (14.35%) | (0.95%) | (5.92%) | (0.68%) | (15.44%) | (30.27%) |
EBT Margin
|
|||
| (1) | (1) | 0 | (1) | (1) | 0 | (1) | 0 | (3) | (6) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 1.64 | 1.13 | 1.23 | 1.78 | 2.29 | 2.41 | 3.00 | 3.71 | 3.15 | 2.81 |
Revenue/Sh
|
|||
| (0.45) | (0.36) | (0.12) | (0.15) | (0.33) | (0.02) | (0.18) | (0.03) | (0.49) | (0.85) |
Earnings/Sh
|
|||
| (0.37) | (0.24) | 0.03 | (0.27) | (0.14) | 0.01 | (0.18) | (0.01) | (0.44) | (0.52) |
Cash Flow/Sh
|
|||
| 0.01 | (0.01) | (0.01) | (0.04) | (0.04) | (0.03) | (0.03) | (0.01) | (0.05) | (0.03) |
Capex/Sh
|
|||
| (0.36) | (0.25) | 0.02 | (0.31) | (0.17) | (0.02) | (0.21) | (0.02) | (0.49) | (0.56) |
Free CF/Sh
|
|||
| 0.25 | 0.20 | 0.17 | 0.88 | 0.64 | 0.78 | 1.72 | 2.13 | 1.66 | 1.81 |
Book Value/Sh
|
|||
| 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 6 | 7 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.97 | 1.59 | 1.29 | 1.92 | 1.90 | 2.09 | 1.99 | 1.66 | 1.98 | 1.74 |
PS Ratio
|
|||
| 6.46 | 8.96 | 9.23 | 3.88 | 6.80 | 6.50 | 3.48 | 2.89 | 3.75 | 2.71 |
PB Ratio
|
|||
| 0.96 | 1.56 | 1.19 | 1.59 | 1.79 | 2.02 | 2.11 | 1.65 | 2.13 | 1.75 |
EV/Sales
|
|||
| (4.43) | (7.01) | 88.10 | (9.17) | (23.58) | (284.97) | (30.44) | (259.56) | (13.64) | (8.82) |
EV/FCF
|
|||
| (1) | (1) | 0 | (1) | (1) | 0 | (1) | 0 | (3) | (4) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| (1) | (1) | 0 | (1) | (1) | 0 | (1) | 0 | (3) | (4) |
FCF
|
|||
| 1 | 0 | 0 | 3 | 2 | 2 | 2 | 5 | 2 | 4 |
Working Cap'
|
|||
| 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 3 | 2 |
Total Debt
|
|||
| 0 | 0 | 0 | (2) | 0 | (1) | 2 | 0 | 3 | 0 |
Net Debt
|
|||
| 1 | 1 | 1 | 3 | 3 | 3 | 9 | 12 | 10 | 12 |
Sh' Equity
|
|||
| (49.69%) | (51.30%) | (16.30%) | (12.29%) | (20.60%) | (1.63%) | (8.09%) | (0.79%) | (16.10%) | (31.50%) |
ROA
|
|||
| (115.91%) | (135.14%) | (123.86%) | (34.70%) | (34.33%) | (20.06%) | (8.76%) | (3.36%) | (13.23%) | (28.09%) |
ROIC
|
|||
| (165.03%) | (175.72%) | (62.62%) | (31.21%) | (46.39%) | (3.31%) | (14.97%) | (1.38%) | (26.69%) | (51.78%) |
ROE
|
|||
Precision Optics Corp. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NEPH Nephros Inc. | $45.0M | 27.2× | Compare |
| ZTEKF Zentek Ltd. | $62.3M | 0.0× | Compare |
| DXR Daxor Corporation | $66.5M | 5.1× | Compare |
| MLSS Milestone Scientific, Inc. | $37.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HBIO Harvard Bioscience, Inc. | $36.5M | 0.0× | Compare |
| MBOT Microbot Medical Inc. | $88.0M | 0.0× | Compare |
| NYXH Nyxoah SA | $129.3M | 0.0× | Compare |
| STXS Stereotaxis Inc. | $133.3M | 0.0× | Compare |
Precision Optics Corp. (POCI) key facts
- Precision Optics Corp. (POCI) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Precision Optics Corp.’s revenue for fiscal 2025 (year ended June 2025) was $19.1 million, roughly unchanged from fiscal 2024.
- Precision Optics Corp. reported a net loss of $5.8 million, or a loss of $0.85 per share, for fiscal 2025.
- As of September 25, 2026, POCI traded at $4.63, a market capitalization of $52.3 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.2× sales.
- Return on equity was −51.8% and debt-to-equity 0.07.
Precision Optics Corp. (POCI) Latest News
17 Sep
Precision Optics Corp. secures initial engineering order from new satellite optical communications customer. Initial order opens potential new revenue stream in satellite optics but remains early-stage without confirmed volume or long-term commitments.
10 Sep
Precision Optics Corp. secures $1.3 million in follow-on production orders from a large defense company. $1.3 million defense orders increase revenue and reinforce competitive standing.
14 May
Precision Optics Corporation (POCI) stock surged over 23% overnight, prompting analysis of the driving factors. 23% overnight stock surge signals major positive catalyst with potential to significantly alter investor sentiment and company trajectory.
Precision Optics Corp. (POCI) reported record Q3 2026 revenue in earnings call, alongside strategic initiatives boosting growth outlook. Record revenue and strategic highlights indicate major positive shifts in financials and positioning for POCI.
13 May
Precision Optics Corp. (POCI) released Q3 2026 earnings call transcript detailing quarterly financial performance, operational updates, and forward guidance. Q3 2026 earnings transcript discloses financial results, strategic updates, and outlook that could significantly sway POCI's market performance and investor confidence.
Precision Optics Corp. (POCI) released the full transcript of its Q3 2026 earnings call. Earnings call transcripts disclose quarterly financials, guidance, and strategic updates that significantly shape investor sentiment and stock trajectory.
Precision Optics Corp. (POCI) reported third quarter fiscal year 2026 financial results. Quarterly financial results disclosure influences financial performance and investor sentiment moderately.
5 May
Precision Optics Corp. (POCI) received a $3.5 million follow-on production order for its single-use ophthalmic program. $3.5 million follow-on order delivers substantial revenue and validates ongoing demand for POCI's single-use ophthalmic products.
8 Apr
Precision Optics Corporation insiders purchased US$1.48 million worth of company stock, increasing their holdings and signaling confidence in future prospects. Insider purchases totaling $1.48m demonstrate leadership confidence, likely enhancing investor sentiment and stock performance moderately.
27 Mar
Precision Optics Corporation, Inc. priced an upsized $10 million public offering of 2,222,223 shares of common stock at $4.50 per share, expecting gross proceeds of $10 million before expenses, with closing on or about November 8, 2024. Upsized $10 million public offering provides substantial capital for growth initiatives and strengthens financial position.
26 Mar
Precision Optics Corporation, Inc. (POCI) announces a proposed public offering of common stock. Proposed public offering represents a major strategic capital raise that could fund growth but dilute existing shares.
18 Feb
Precision Optics Corp. (POCI) reported record Q2 2026 revenue in earnings call, driven by strong demand in medical and defense sectors, despite margin compression from higher costs and investments. Record revenue highlights robust growth and market demand, significantly enhancing future performance outlook despite margin pressures.
17 Feb
Precision Optics Corporation reported second quarter fiscal year 2026 revenue of $6.2 million, up 14% from prior year, with net income of $0.4 million versus a $0.1 million loss last year. Gross margin improved to 28%, backlog reached $15 million, and management reaffirmed full-year guidance amid strong demand in endoscopy and aerospace. Quarterly revenue growth and profitability improvement moderately influence financial performance and market sentiment without fundamentally altering long-term trajectory.
13 Feb
Precision Optics Corporation, Inc. (POCI) released its Q2 2026 earnings call summary, detailing quarterly financial performance, operational updates, and future outlook. Quarterly earnings summaries impact financial performance and investor sentiment but depend on results for broader trajectory changes.
12 Feb
Materion Corporation reported its Q4 2025 earnings, highlighting strong financial performance driven by increased demand in key sectors. The company noted significant growth in revenue and net income compared to the previous quarter, attributed to strategic investments and operational efficiencies. Management provided an optimistic outlook for 2026, emphasizing continued focus on innovation and market expansion. Challenges such as supply chain disruptions were acknowledged, but the overall sentiment remained positive regarding future growth prospects. The earnings report indicates moderate growth and operational improvements that could influence Precision Optics Corp.'s market positioning.
14 Nov
Precision Optics Corp. (POCI) reported record revenue for Q1 2026, highlighting strong financial performance and strategic initiatives aimed at enhancing growth. The company emphasized its commitment to innovation and expanding its market presence, which is expected to drive future success. Record revenue and strategic initiatives indicate significant potential for future growth and market performance.
13 Nov
Precision Optics Corp. (POCI) reported its financial results for the first quarter of fiscal year 2026, highlighting significant revenue growth and improved profitability. The company attributed its success to increased demand for its optical products and advancements in technology. Management expressed optimism about future growth prospects and ongoing investments in research and development. The results reflect a positive trend in the company's performance, positioning it favorably in the competitive landscape. The reported revenue growth and profitability improvements indicate significant positive momentum for the company's future performance.
11 Nov
Precision Optics Corp. has entered into a product development agreement to create a custom high-end borescope specifically designed for jet engines. This collaboration aims to enhance inspection capabilities and improve maintenance processes in the aerospace sector, potentially leading to increased efficiency and safety in jet engine operations. The development of a specialized borescope for jet engines represents a significant strategic move that could enhance Precision Optics' competitive positioning in the aerospace market.
7 Nov
Precision Optics Corp. (POCI) has entered into a product development agreement aimed at creating next-generation augmented reality sub-systems specifically designed for fighter pilots. This collaboration is expected to enhance the capabilities of pilot training and operational effectiveness through advanced technology integration. The agreement represents a significant strategic move that could enhance POCI's competitive positioning and market presence in defense technology.
29 Oct
Materion Corporation reported strong financial results for the third quarter of 2025, highlighting increased revenues and profits. The company affirmed its full-year outlook, indicating confidence in its operational performance and market conditions. Key drivers of growth included demand in various sectors and effective cost management strategies. Strong financial results and affirmed outlook may influence market sentiment and operational aspects for related companies.
29 Sep
Precision Optics Corp. (POCI) reported record revenue in Q4 2025, highlighting significant growth and strategic initiatives aimed at enhancing market position. The earnings call emphasized the company's commitment to innovation and expanding its product offerings, which are expected to drive future performance. Record revenue and strategic initiatives indicate a significant impact on future performance and market positioning.
Precision Optics Corp. (POCI) reported its financial results for the fourth quarter and fiscal year 2025, highlighting significant growth in revenue and improvements in profitability. The company achieved a year-over-year revenue increase, driven by strong demand for its optical products. Management expressed optimism about future growth prospects and ongoing investments in technology and product development. The results reflect POCI's strategic initiatives to enhance its market position and operational efficiency. The financial results indicate significant growth and strategic initiatives that could alter the company's trajectory and investor sentiment.
5 Jun
Precision Optics Corporation is relocating its corporate offices from Gardner, MA to Littleton, MA to enhance production capabilities and address a growing backlog. The move, effective August 1, 2025, will consolidate production in Gardner and allow access to a broader engineering talent pool. The company aims to meet increasing demands in the medical and defense/aerospace sectors. The relocation and expansion of facilities are significant strategic moves that are expected to enhance production capacity and access to talent, impacting future performance.
17 May
Precision Optics Corporation (NASDAQ:POCI) reported a net loss of US$2.10 million for the third quarter of 2025, widening from a loss of US$0.32 million in the same period last year. Revenue decreased by 20% to US$4.19 million, resulting in a loss per share of US$0.30, compared to a loss of US$0.052 in 3Q 2024. The company's shares have declined by 2.4% over the past week. Additionally, there are four warning signs identified that investors should consider before investing. The significant widening of losses and declining revenue indicate potential challenges that could impact the company's future performance and investor sentiment.
15 May
Precision Optics Corporation (POCI) reported third quarter fiscal year 2025 results, with revenue of $4.2 million, down from $5.2 million year-over-year. Production revenue increased slightly to $3.3 million, while engineering revenue fell to $0.9 million. Gross margins dropped to 10%, and the net loss widened to $2.1 million. The company launched the Unity Imaging Platform and secured a Main Purchase Agreement with a top aerospace company, ensuring minimum annual purchases of nearly $4 million through 2026. Despite production challenges with single-use cystoscopes, the CEO expressed optimism for a positive fourth quarter, anticipating revenue growth and improved EBITDA. A $5.1 million stock offering was also closed to support expansion. The launch of the Unity Imaging Platform and significant aerospace agreements are likely to significantly impact future performance.
21 Apr
Precision Optics Corp. (POCI) is scheduled to present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. This event will provide an opportunity for the company to showcase its advancements and engage with potential investors. Participation in a prominent investment showcase may enhance visibility and investor interest, impacting market sentiment.
3 Apr
Precision Optics Corporation has secured a Main Purchase Agreement with a top-tier aerospace customer, resulting in $3.1 million in new orders and a program backlog of $6.6 million expected to be delivered over the next 12 months. The company anticipates an additional $3.9 million in commitments for 2026. To meet demand, Precision Optics has doubled its clean room production capacity. The agreement ensures a minimum purchase commitment of nearly $4 million annually through 2026, enhancing predictability in production schedules. The execution of a significant purchase agreement and increased production capacity are likely to have a substantial impact on future performance and investor sentiment.
20 Mar
Precision Optics Corp. has appointed Joseph P. Pellegrino, Jr. to its Board of Directors, enhancing its leadership team. Pellegrino brings extensive experience in the medical device industry, which is expected to benefit the company's strategic direction and growth initiatives. The appointment of a seasoned industry professional may positively influence the company's strategic direction and operational effectiveness.
5 Mar
Precision Optics Corp. (POCI) is highlighted as one of three penny stocks with market caps under $80 million, suggesting potential investment opportunities. The article emphasizes the company's innovative technologies and growth prospects within the medical device sector, which could attract investor interest. POCI's focus on precision optics positions it favorably in a competitive market, potentially leading to increased market performance. POCI's innovative technologies and growth prospects may moderately influence its financial performance and competitive positioning.
4 Mar
Precision Optics Corporation has appointed Buell Duncan to its Board of Directors, enhancing its leadership with his extensive experience in technology and business. Duncan previously held senior roles at IBM and is currently involved with several venture capital and advisory positions. His appointment follows the retirement of Dr. Richard Miles, who served on the board for 20 years. The company focuses on advanced optical instruments for medical and defense/aerospace industries, leveraging proprietary technologies to meet market demands. The appointment of Buell Duncan is expected to moderately influence the company's strategic direction and market positioning.